Press Releases

August 3, 2021 at 7:00 AM EDT

Summary Toggle Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

Singapore is the second country to approve the advancement of ARCT-154 into clinical development ARCT-154 and ARCT-165 elicit high levels of neutralizing antibodies in non-human primates against multiple variants of concern SAN DIEGO --(BUSINESS WIRE)--Aug.

PDF Version
August 2, 2021 at 9:00 AM EDT

Summary Toggle Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

The Phase 1/2/3 trial to be funded and sponsored by Arcturus’ manufacturing partner Vinbiocare ARCT-154 to be developed in parallel with ARCT-021, Arcturus’ lead investigational COVID-19 vaccine SAN DIEGO --(BUSINESS WIRE)--Aug. 2, 2021-- Arcturus Therapeutics Holdings Inc.

PDF Version
August 2, 2021 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

Arcturus will receive $40 million upfront payment and potential royalties based on vaccines produced SAN DIEGO --(BUSINESS WIRE)--Aug. 2, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the

PDF Version
July 28, 2021 at 8:30 AM EDT

Summary Toggle Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO --(BUSINESS WIRE)--Jul. 28, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
July 26, 2021 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

SAN DIEGO --(BUSINESS WIRE)--Jul. 26, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
July 6, 2021 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, Calif. --(BUSINESS WIRE)--Jul. 6, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
June 9, 2021 at 9:00 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
May 10, 2021 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3 In negotiations with multiple regulatory authorities regarding ARCT-021 Phase 3 study program Continued progress advancing mRNA therapeutic

PDF Version
May 3, 2021 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021

SAN DIEGO --(BUSINESS WIRE)--May 3, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
March 30, 2021 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version